Launch of chimeric anti-mouse PD1 and PD-L1 recombinant antibodies

Leinco Technologies a biotechnology company and specialty manufacturer of antibodies, recombinant proteins, ELISA kits, and second step reagents today announced the launch of the mAbMods™ chimeric anti-mouse PD1 and PD-L1 recombinant antibodies to target mouse programmed cell death receptor 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) in in vivo functional studies. These antibodies are the first in a line of mouse anti-mouse antibodies to be launched in the coming months. They are designed to mitigate the immunogenicity problems associated with the use of antibodies from other species such as rat or hamster in experiments using mouse models, particularly during prolonged use.

“We are answering the needs of researchers in discovery and translational sciences working on mouse models”, said Pat Leinert Sr., Leinco CSO. “Meeting our stringent product specifications, these mouse anti-mouse antibodies have been developed to help our customers increase the reproducibility of data from in vivo functional studies and extend the duration of their experiments with mouse models, while expanding our range of specialized recombinant antibodies and giving researchers the choice, availability and quality, they need for their work.”

The recombinant monoclonal antibodies have identical antigen binding variable domains to those of the traditional clones from which they are derived, but the IgG constant regions are from the mouse. The antibodies are also available in an Fc Muted™ format, in which mutations have been introduced at crucial binding sites of the Fc domain with the FcR and C1q, to reduce or eliminate the Fc-mediated effector functions that can lead to unwanted side effects. The research-use-only recombinant antibodies meet stringent product specifications. They are free of additives or preservatives, have low endotoxin levels, and undergo Infectious Microbe PCR AmplifiCation test (IMPACT) testing. These attributes make them invaluable reagents for the generation of highly reproducible results in in vitro assays and in in vivo functional assays.

Chimeric anti-mouse PD1 and PD-L1 recombinant antibodies are of particular interest in investigations on the efficacy and toxicity of immunotherapy, which is based on antibodies that function as immune checkpoint inhibitors (ICIs) as an important strategy for the treatment of malignant tumors. PD-L1 is highly expressed in a variety of malignancies. PD-L1 binds to its receptor, PD-1, found on immune cells including activated T cells, B cells, and myeloid cells and this interaction functions as a break to immune responses. Monoclonal antibodies targeting PD-L1 and PD-1 block their interaction, which activates the immune response against the tumor.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>